FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

JUBILANT

680.5
+15.85 (2.38%)
Updated 03:28 02/07 IST

JUBILANT Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for JUBILANT
Disclaimer
0% Bullish
0% Bearish

JUBILANT Buy or Sell - Brokerage Reports

No. of reports in last year
6
No. of analysts
3
Average Consensus Forecast
689.17
Consensus Potential
-3.48%
See JUBILANT Share Price Targets >>

JUBILANT Ratings

Long term JUBILANT rating by FrontPage users
4.3/5 (4 Ratings)
Find answers to all your questions on live JUBILANT message board: Is JUBILANT buy or sell? Should I buy JUBILANT shares? Why are JUBILANT shares falling? Should I invest in JUBILANT stock?

  1. Home
  2. JUBILANT Forum

JUBILANT Share Price Discussion

N
Reputation: 3,547 • Jun 23 10:36 AM
Dassault Systèmes demonstrates innovations for the life sciences industry in India
The event focused on transforming and digitalizing the life sciences industry in India, which is undergoing core shifts in business processes and manufacturing operations to make it more agile and adaptable.
The Economic Times
Like
Reply
D
Reputation: 0 • Jun 19 9:23 AM

Stock is loosing steam.
Exchange Disseminated Time 19/06/2020 12:23:20
The Exchange has sought clarification from Jubilant Life Sciences Ltd on June 19, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant inf...
Read more...
Like
Reply
T
Reputation: -15,649 • Jun 18 12:54 PM

IDX:NIFTY 50 - 916239
CS on Consumer Cos
COVID’s continued spread to extend consumer caution beyond earlier expectations in large cities
Downgrade Avenue to U-P from Neural
Downgrade Jubilant to Neutral from O-P
Cut earnings by 4-12% for Avenue, Jubilant, Asian Paints, Page, Pidilite, HUL, USL & Emam...
Read more...
Like
Reply

Type
Sell
Instrument
JUBILANT
Entry Price
₹660
Price@Trade
₹656.5
Target Price
₹654
Stop Price
₹666
Valid Till
Jun 16, 2020 3:20 AM
Margin
₹66,000 approx for 100 Qty
Status
Target Achieved
Exit Price
₹654
Net P&L
+₹600 (+0.91%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 16 6:50 AM

Update
Trade Entered
Entry Price
₹660
TrackerBot @trackerbot
Jun 16 7:06 AM

Update
Target Achieved
Exit Price
₹654
N
Reputation: 3,547 • Jun 16 6:23 AM
Jubilant Life share at 52-week high as Rakesh Jhunjhunwala raises stake
Rakesh Radheshyam Jhunjhunwala held 4.41 percent stake (or 70.25 lakh equity shares) in the pharma company as per March shareholding pattern available on exchanges.
Moneycontrol
Like
Reply
T
Reputation: -15,649 • Jun 16 6:11 AM

Rakesh Jhunjhunwala bought additional 6 lakh shares of Jubilant Life Sciences via open market on June 15, reported CNBC-TV18.
Like
Reply

Type
Buy
Instrument
JUBILANT
Entry Price
₹679
Price@Trade
₹675.2
Target Price
₹780
Stop Price
₹625
Valid Till
Jul 15, 2020 3:20 AM
Margin
₹67,900 approx for 100 Qty
Status
Active
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jun 15 8:51 AM

Update
Trade Entered
Entry Price
₹679
N
Reputation: 3,547 • Jun 15 4:08 AM
CDSCO reviewing Remdesivir applications on priority basis
"Being an injectable formulation, testing for assay, identity, impurities, bacterial endotoxin test and sterility become very critical for patient safety and this data need to be provided by the companies," it added.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 15 1:51 AM
Buy Jubilant Life Sciences, target price Rs 867: Anand Rathi
The brokerage continues to remain positive on the company on a medium to longer term perspective and maintains a buy rating on the stock.
The Economic Times
Like
Reply
N
Reputation: 3,547 • Jun 14 9:28 AM
Buy Jubilant Life Sciences; target of Rs 867: Anand Rathi
Anand Rathi is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 867 in its research report dated June 12, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 12 12:38 PM
Why wait for Gilead's antiviral Remdesivir may not end soon?
Indian drug regulator has been reviewing the marketing authorisation applications of Remdesivir of four Indian companies: Cipla, Hetero, Jubilant Life Sciences and BDR Pharmaceuticals
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 9 1:03 AM
Exclusive: Bangladesh companies don't have licence to sell Remdesivir in India
CDSCO hasn't received application from any Bangladesh companies for Remdesivir import licence.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 8 1:08 AM
A Bangladesh pharma company causes heartburn in India's drugmakers
Eskayef Pharma had been quick to take advantage of international trade rules that allow nations defined by the United Nations as least-developed countries to ignore patents and produce affordable drugs.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 8 12:13 PM
Has this Bangladesh drugmaker trumped Indian counterparts on Gilead's Remdesivir?
Eskayef Pharma had been quick to take advantage of international trade rules that allow nations defined by the United Nations as least-developed countries to ignore patents and produce affordable drugs.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 4 2:01 AM
Indian licensees free to price Remdesivir: Gilead
US drug maker to launch own brand of Covid-19 experimental drug in the country next month. Gilead has licensed the drug to four companies — Cipla, Mylan, Hetero and Jubilant Life Sciences — for sale in India, but none of these firms has received approval from the drug controller. most of the four companies are ready with their products and are awaiting nod from the regulator to manufacture and start selling the drug in the country.
The Economic Times
Like
Reply
N
Reputation: 3,547 • Jun 2 5:08 AM
Hold Jubilant Life Sciences; target of Rs 414: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Jubilant Life Sciences with a target price of Rs 414 in its research report dated Jun 01, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 2 2:23 AM
Buy Jubilant Life Sciences; target of Rs 550: ICICI Direct
ICICI Direct is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 550 in its research report dated Jun 01, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 1 4:33 AM
Gilead gets conditional approval from India regulator to market remdesivir for COVID-19
The conditional marketing authorisation for remdesivir was granted under the accelerated review process considering the emergency situation and unmet medical needs
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 1 8:58 AM
Buy Jubilant Life Sciences; target of Rs 515: Motilal Oswal
Motilal Oswal is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 515 in its research report dated May 30, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,547 • Jun 1 4:33 AM
COVID-19 crisis | Remdesivir manufacturers may be allowed to sell only to government for now: Report
Gilead Sciences' experimental drug remdesivir has been found to aid recovery of COVID-19 patients.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • JUBILANT - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization10,580.71
    Enterprise Value12,147.97
    Price to Earnings50.87
    Price to Book Value4.52
    Return on Capital Employed0.14
    Return on Equity0.12
    Face Value1
    Dividend YieldNA
  • JUBILANT - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    1-Feb-20Nirmal BangBuy792
    31-Jan-20Prabhudas LilladherReduce488
    29-Oct-19Nirmal BangBuy792
    25-Oct-19Prabhudas LilladherReduce433
    29-Jul-19Nirmal BangBuy785
    JUBILANT Brokerage Price Target
  • JUBILANT Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 2673696.95667.1679.65
    Jul 1660671657.45664.65
    Jun 30656674649655.45
    Jun 29660.7660.7645649.55
    Jun 26667677649.5654.7
  • JUBILANT Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹636.98
    30 Day Moving Average₹580.63
    50 Day Moving Average₹512.47
    100 Day Moving Average₹465.24
    200 Day Moving Average₹497.36
  • JUBILANT - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue3,3062,491.220.33
    Operating Profit5393180.69
    Profit Before Tax368114.522.21
    Net Income26379.192.32
  • JUBILANT - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,3402,2490.04
    Total Liabilities2,5232,605-0.03
    Total Assets4,8644,8540
  • JUBILANT - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity558419.150.33
    Cash from Investing Activity-127-43.071.95
    Cash from Financing Activity-470-338.40.39
    Net Cash Flow-4037.69-2.06
  • JUBILANT - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.050.02
    Return on Equity0.120.04
    Return on Capital Employed0.140.08
  • JUBILANT - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.04
    3 Year CAGR Growth in Operating Profit128.73
    3 Year CAGR Growth in EBIDTANA
    3 Year CAGR Growth in Net Income0.28
    3 Yr CAGR Growth - Diluted EPS0.28
  • JUBILANT - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.05
    5 Year CAGR Growth in Operating Profit0.47
    5 Year CAGR Growth in EBIDTA0.46
    5 Year CAGR Growth in Net Income7.07
    3 Yr CAGR Growth - Diluted EPS7.07
  • JUBILANT - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 23 10:36 AM
    Dassault Systèmes demonstrates innovations for the life sciences industry in India
    The Economic Times
    NewsBot
    Jun 16 6:23 AM
    Jubilant Life share at 52-week high as Rakesh Jhunjhunwala raises stake
    Moneycontrol
    NewsBot
    Jun 15 1:51 AM
    Buy Jubilant Life Sciences, target price Rs 867: Anand Rathi
    The Economic Times
    NewsBot
    Jun 14 9:28 AM
    Buy Jubilant Life Sciences; target of Rs 867: Anand Rathi
    Moneycontrol
    NewsBot
    Jun 2 5:08 AM
    Hold Jubilant Life Sciences; target of Rs 414: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    Jun 2 2:23 AM
    Buy Jubilant Life Sciences; target of Rs 550: ICICI Direct
    Moneycontrol
    NewsBot
    Jun 1 8:58 AM
    Buy Jubilant Life Sciences; target of Rs 515: Motilal Oswal
    Moneycontrol
    NewsBot
    May 29 2:23 AM
    Jubilant Life Sciences posts Rs 260.49 crore profit for March quarter
    Moneycontrol
    NewsBot
    May 17 3:08 AM
    Buy Jubilant Lifesciences; target of Rs 510: Motilal Oswal
    Moneycontrol
    NewsBot
    May 13 3:58 AM
    Jubilant Life shares hit 5% upper circuit after deal with Gilead to produce COVID-19 vaccine
    Moneycontrol
  • JUBILANT - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020